ATRA has revolutionized the treatment of APL, a subtype of AML (about 5–10% of all AML) characterized by the PML-RARα (PML-RARA) fusion protein, arising from a balanced translocation involving theRARA gene on chromosome 17 and thePML gene on chromosome 15. Here, PML is linked to acute myeloid leukemia.